<p>Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database</p>-Reference-Cited by-同舟云学术

Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database

Published:2020-11 Issue: Volume:Volume 12 Page:207-215
ISSN:1179-1365
Container-title:Drug, Healthcare and Patient Safety
language:en
Short-container-title:DHPS

Author:

Matsumura Yumi

Publisher

Informa UK Limited

Subject

Health Policy,Pharmacology

Reference34 articles.

1. Meningococcal disease and the complement system

2. Soliris Review Report (October 16, 2019). Available from http://www.pmda.go.jp/drugs/2019/P20191205001/870056000_22200AMX00316_A100_1.pdf. Accessed January 17, 2020.

3. Soliris Review Report (November 24, 2017). Available from http://www.pmda.go.jp/drugs/2018/P20180110001/870056000_22200AMX00316_A100_2.pdf. Accessed January 17, 2020.

4. Clinical recognition of meningococcal disease in children and adolescents

5. European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Available from https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet. Accessed January 3, 2020.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms;Drug Discovery Today;2024-09

2. Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports;Expert Opinion on Drug Safety;2024-08-26

3. Thrombotische Mikroangiopathie;TumorDiagnostik & Therapie;2024-03

4. Effektivität neuer Therapien bei der Myasthenia gravis im Vergleich;InFo Neurologie + Psychiatrie;2024-02

5. Eculizumab in myasthenia gravis: A review;Saudi Journal of Ophthalmology;2024-01